Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

by Schönland, Stefan , Gatt, Moshe E , Hungria, Vania , Roeloffzen, Wilfried , Lam, Selay , Lu, Jin , Jaccard, Arnaud , Venner, Christopher P , Bhutani, Divaya , Hansen, Timon , Comenzo, Raymond L , Libby, Edward , Waxman, Adam J , Tran, NamPhuong , Gibbs, Simon , Jamroziak, Krzysztof , Zonder, Jeffrey A , Minnema, Monique C , Palladini, Giovanni , Weiss, Brendan M , Tromp, Brenda , Crusoe, Edvan , Suzuki, Kenshi , Kim, Kihyun , Merlini, Giampaolo , Schecter, Jordan M , Cibeira, M. Teresa , Bumma, Naresh , Huart, Antoine , Mollee, Peter , Vasey, Sandra Y , Dimopoulos, Meletios A , Lee, Hans C , Goodman, Stacey A , Vermeulen, Jessica , Song, Kevin , Kwok, Fiona , Kim, Jin-Seok , Shimazaki, Chihiro , Beksac, Meral , Sanchorawala, Vaishali , Ahmadi, Tahamtan , Manier, Salomon , Rosenzweig, Michael , Wong, Sandy W , Qin, Xiang , Zhuang, Sen H , Wechalekar, Ashutosh D , Valent, Jason , Kastritis, Efstathios

in Adverse events / Amyloidosis / Blood diseases / Bortezomib / Cardiomyopathy / CD38 antigen / Cyclophosphamide / Dexamethasone / Diarrhea / Fibrils / Heart / Hematology / Human health and pathology / Immunoglobulins / Immunotherapy / Inhibitor drugs / Leukemia / Life Sciences / Light / Light chains / Lymphoma / Lymphopenia / Medical prognosis / Monoclonal antibodies / Multiple myeloma / Oncology / Patients / Plasma cells / Targeted cancer therapy / Treatments in Oncology

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

2021

Confirm

Do you wish to request the book?

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Schönland, Stefan,

Gatt, Moshe E,

Hungria, Vania,

Roeloffzen, Wilfried,

Lam, Selay,

Lu, Jin,

Jaccard, Arnaud,

Venner, Christopher P,

Bhutani, Divaya,

Hansen, Timon,

Comenzo, Raymond L,

Libby, Edward,

Waxman, Adam J,

Tran, NamPhuong,

Gibbs, Simon,

Jamroziak, Krzysztof,

Zonder, Jeffrey A,

Minnema, Monique C,

Palladini, Giovanni,

Weiss, Brendan M,

Tromp, Brenda,

Crusoe, Edvan,

Suzuki, Kenshi,

Kim, Kihyun,

Merlini, Giampaolo,

Schecter, Jordan M,

Cibeira, M. Teresa,

Bumma, Naresh,

Huart, Antoine,

Mollee, Peter,

Vasey, Sandra Y,

Dimopoulos, Meletios A,

Lee, Hans C,

Goodman, Stacey A,

Vermeulen, Jessica,

Song, Kevin,

Kwok, Fiona,

Kim, Jin-Seok,

Shimazaki, Chihiro,

Beksac, Meral,

Sanchorawala, Vaishali,

Ahmadi, Tahamtan,

Manier, Salomon,

Rosenzweig, Michael,

Wong, Sandy W,

Qin, Xiang,

Zhuang, Sen H,

Wechalekar, Ashutosh D,

Valent, Jason,

Kastritis, Efstathios

2021

Overview

In a randomized trial of bortezomib, cyclophosphamide, and dexamethasone as compared with the same therapy plus daratumumab, patients with light-chain amyloidosis who received daratumumab had a higher frequency of hematologic complete response than those who did not (53.3% vs. 18.1%). Deaths were most commonly due to cardiac failure.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject